NEW YORK (GenomeWeb) – Myriad Genetics announced today that it has signed an expanded companion diagnostics research partnership agreement with AbbVie. The drug developer will use Myriad's myChoice HRD companion diagnostic and a menu of tumor tests to identify non-small cell lung cancer patients who would be likely to respond to AbbVie's PARP inhibitor, veliparib, in combination with chemotherapy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.